JNJ·Johnson & Johnson
JNJ|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.42 | - | - |
| Q2'26 | $2.87 | $2.90 | +0.9% |
| Q1'26 | $2.88 | $2.70 | -6.4% |
| Q4'25 | $2.46 | $2.46 | -0.1% |
| Q3'25 | $2.76 | $2.80 | +1.5% |
| Q2'25 | $2.68 | $2.77 | +3.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $25.6B | - | - |
| Q2'26 | $25.3B | $25.3B | +0.0% |
| Q1'26 | $25.0B | $24.1B | -3.9% |
| Q4'25 | $24.4B | $24.6B | +0.7% |
| Q3'25 | - | $24.0B | - |
| Q2'25 | - | $23.7B | - |
Market Data
JNJ Stock Snapshot
JNJ is currently trading at $271.95, giving Johnson & Johnson a market cap of 629.71B and a P/E ratio of 29.9. Today's range spans $268.00–$273.80, with shares opening at $271.00 and moving up $0.95 (0.4%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 78/100.
Over the past year JNJ has traded between $173.33 and $276.47 - the current price is +56.9% off the 52-week low and -1.6% from the high. 33 analysts cover the stock with a Buy consensus and a mean 12-month target of $272.50 (range $190.00–$305.00), implying upside of +0.2%.
Cross-sector analysis highlights JNJ as a bullish outlier even among its mega-cap Healthcare peers - 86/100 technical score, BUY signal, bullish sentiment (78/100), price $271.95 (near 52-week highs in $173.33–$276.47). The current P/E ratio stands at 29.9. At 629.71B in capitalization, relative strength at this scale typically signals either sector leadership or a stock-specific earnings catalyst on the horizon - either way, the setup argues for attention rather than indifference.
For portfolio managers constructing Healthcare exposure, a mega-cap with a BUY signal and bullish news backdrop represents the kind of conviction-generating setup that justifies moving from benchmark weight to overweight. The 86/100 technical score at $271.95 (near 52-week highs) provides the entry discipline; the 629.71B market cap provides the exit liquidity, a combination most position-sizing frameworks actively seek.
Company Insights: Johnson & Johnson (JNJ)
Johnson & Johnson’s current valuation sits at a market cap of $624.7 billion, with a share price of $259.72 that has delivered a 27.2 % return over the past year. The stock is 30.9 % above its 52‑week low and 19.1 % below its 52‑week high, indicating a compressed upside window. Forward earnings estimates place the company at a P/E of 29.7x, well below the peer group average of 53.0x, suggesting relative value. Dividend yield hovers around 2.7 %, providing a steady income stream for yield‑oriented investors. Analyst consensus targets $272.5, a modest 5 % premium to the current price, tightening the earnings‑multiple compression.
In Q1 2026, JNJ missed EPS estimates by $0.18 and revenue fell short by $0.97 billion, while Q2 2026 produced a $0.03 billion EPS beat and a $0.01 billion revenue beat. This oscillation illustrates earnings volatility despite steady top‑line growth, as revenue climbed 9.6 % YoY in Q4 2025 and 10.2 % in Q1 2026. Management must navigate these swings while maintaining its robust dividend policy. The company’s diversified portfolio of innovative medicine and MedTech products mitigates concentration risk. Investor sentiment has been falling over the last 14 days, with a score of 73 and a delta of –16, reflecting a temporary market correction.
Analyst consensus sits at $272.5, implying only a 5 % upside from the current price and a 12 % upside from the 52‑week midpoint of $259. The high target of $305 represents a 17 % premium, compressing potential gains. The low target of $190 is 27 % below the 52‑week low, offering a distant downside floor. Sentiment trends suggest that the stock may rebound if earnings beats continue to outpace expectations. The company’s strong cash flow generation supports ongoing capital returns. The current valuation reflects a market that has priced in most of the recent legal settlement and MedTech expansion.
The $5.5 billion talc settlement removes a long‑standing legal risk and improves cash flow, while a $1 billion investment in contact‑lens manufacturing opens a Medicare‑reimbursed revenue stream. FDA approval of the OTTAVA robotic system signals continued MedTech expansion. Leadership transition may recalibrate R&D priorities, potentially affecting the pipeline. The company’s scale provides pricing power against smaller rivals. Dividend stability remains a key attractor amid earnings volatility. Monitoring regulatory approvals and Medicare reimbursement updates will be crucial for next‑quarter earnings dynamics.
Valuation Discipline
Current share price sits close to the 52‑week high, leaving a narrow upside window for new investors.
The forward P/E of 29.7x is well below the peer group average of 53.0x, suggesting relative valuation attractiveness.
Analyst consensus target of $272.5 is only 5% above the current level, tightening the earnings‑multiple compression.
Earnings Volatility
Q1 2026 EPS miss and revenue shortfall contrast with Q2 beat, highlighting earnings swing.
Revenue growth remained positive year‑over‑year, but EPS fluctuations reflect pricing and cost pressures.
Management must navigate this variability while maintaining dividend commitments.
Dividend Stability
JNJ’s dividend yield sits around 2.7%, historically reliable for income‑focused investors.
The company’s payout ratio stays within a sustainable range despite earnings volatility.
Dividend growth has been steady, providing a cushion against market volatility.
MedTech Momentum
The $5.5 billion talc settlement removes a long‑standing legal risk, improving cash flow.
The $1 billion investment in contact‑lens manufacturing opens a Medicare‑reimbursed revenue stream.
FDA approval of the OTTAVA robotic system signals continued MedTech expansion.
Regulatory & Legal Risks
Past litigation has pressured earnings, but the settlement resolves most exposure.
Ongoing regulatory scrutiny on drug approvals remains a potential headwind.
New leadership may shift R&D priorities, affecting future pipeline timelines.
Market Sentiment
Sentiment score of 73 has fallen over 14 days, indicating a temporary market correction.
The decline is not yet reflected in the share price, offering a potential entry point.
Positive earnings beats can reverse sentiment trends and lift the stock.
Competitive Landscape
JNJ competes with AbbVie, Abbott, and Align, but maintains a diversified portfolio.
Its drug and device segments provide cross‑sell opportunities.
The company’s scale gives it pricing power against smaller rivals.
Positioning JNJ
Given that the current price is 30.9% above the 52‑week low and only 5% below the analyst consensus target, a cautious approach is warranted. Adding exposure when the share approaches the 52‑week low could capture a mean‑reversion play. Reducing exposure is advisable if the stock climbs toward the analyst high target of $305, which would compress upside further. Monitor sentiment shifts and earnings guidance for timing adjustments. Position sizing should reflect the stock’s beta and your overall healthcare allocation.
Risk Factors
Johnson & Johnson’s risk profile is largely company‑specific, driven by uncertainties in its drug pipeline, regulatory approvals for its MedTech devices, and lingering litigation exposure. Macro‑economic pressures play a secondary role, whereas near‑term catalysts, such as trial outcomes, FDA clearance, and reimbursement decisions, can compress the valuation multiple. The most actionable risks are those that could materialize within the next 12 to 18 months and directly impact revenue or cash flow.
- Innovation Pipeline Uncertainty
The company’s future growth hinges on the successful development of new prescription drugs across oncology, immunology, and neuroscience. A failure in a pivotal Phase III trial or a delay in FDA review could stall revenue growth by 5‑10% over the next two fiscal years. Leading indicators include trial enrollment rates, interim data releases, and FDA advisory committee meeting dates, all of which are disclosed quarterly. If a key candidate fails, the company may need to reallocate R&D spend, potentially eroding margins. This risk could materialize as soon as the next quarterly earnings call if trial results are announced.
- MedTech Regulatory Delays
Recent scrutiny over the company’s robotic surgical platform could stall market entry and delay revenue recognition. A delay in FDA clearance or a post‑market safety issue could reduce device sales by 3‑5% in the short term. Watch for FDA clearance announcements, competitor approvals, and any device recall news, which are typically reported in regulatory filings and industry press releases. A regulatory hold could also increase compliance costs and divert resources from other product lines. The impact would likely unfold within the next 6‑12 months, coinciding with the product launch cycle.
- Talc Litigation Residual Exposure
Although a $5.5 billion settlement closed many lawsuits, lingering claims could surface, creating unexpected liabilities. New litigation filings or changes in insurance coverage could trigger a $200‑$400 million charge, eroding cash reserves and earnings. Monitoring legal databases and court docket updates provides early warning of emerging claims. If a significant claim is filed, the company may need to set aside additional reserves, compressing operating income. This scenario could arise over the next two to three years as the legal landscape evolves.
- Contact Lens Medicare Reimbursement Uncertainty
The expansion of contact lens manufacturing hinges on Medicare reimbursement approvals, which remain unconfirmed. A denial or reduction in reimbursement rates could cut projected revenue by 2‑4% in the upcoming fiscal year. Key indicators include CMS reimbursement policy changes, payer negotiations, and industry lobbying efforts, all of which are reported in healthcare policy briefings. A reimbursement setback would also affect the company’s ability to scale production and achieve economies of scale. The risk could become material in the next earnings cycle if Medicare policy decisions are finalized.
- Analyst Target Spread Disagreement
The wide analyst target spread of $115 reflects divergent views on the company’s valuation and growth prospects. A shift toward the lower end of the range could compress the valuation multiple by 10‑15%, impacting the stock price. Leading indicators include analyst revisions, earnings surprises, and macro‑economic data releases, all of which are tracked in earnings conference calls and research reports. If the company misses guidance or faces regulatory setbacks, analysts may downgrade their targets, accelerating the spread. This divergence could manifest during the next earnings season as analysts reassess the company’s risk profile.
Key Metrics for JNJ
Johnson & Johnson’s valuation hinges on how its diversified pipeline and segment mix translate into steady cash flow, while the company’s R&D efficiency and earnings reliability shape investor sentiment. The premium multiple investors pay is largely justified by the pace of drug approvals and the stability of its MedTech revenue streams, yet any slowdown in the pipeline or earnings volatility can erode that premium. Tracking these metrics each quarter offers a clear window into whether the market’s expectations are being met or exceeded.
Valuation Momentum & Consensus Spread: The current share price sits at $259.72, comfortably above the analyst mean target of $272.5 but still 6% below the high of $305.0, indicating a modest upside potential. The spread between the low target of $190.0 and the current price suggests a valuation premium of roughly 37% over the floor, a level that has historically attracted cautious investors. Over the past year, the stock’s 1‑month, 3‑month, and 1‑year returns of 0.4%, 16.8%, and 27.2% respectively have outpaced the broader healthcare sector, signaling positive momentum. When the consensus range narrows, the market often interprets it as growing confidence, which can lift the stock by 2–4%. Analysts will likely revisit their targets in the next earnings cycle, so any widening of the spread could prompt a re‑evaluation of the premium JNJ commands.
What Moves JNJ Stock?
Johnson & Johnson’s share price is most sensitive to the rapid uptake of its MedTech portfolio, especially the newly FDA‑approved OTTAVA robotic surgical system. The drug pipeline and long‑standing dividend policy provide secondary support, while a recent talc settlement introduces a drag. With a 27% return this year and a falling sentiment trend, investors are watching how quickly the market prices in new MedTech revenue and cash‑flow impacts.
MedTech Expansion
The launch of OTTAVA has already begun to lift MedTech revenue, and analysts expect the system’s adoption curve to accelerate as surgeons gain confidence and reimbursement pathways solidify. In Q2 2026, MedTech sales grew 7% year‑over‑year, contributing a higher margin segment that helped JNJ beat EPS estimates despite a revenue miss in Q1. Historical data shows that each new product launch typically pushes the share price up 3–5% on earnings day, reflecting the market’s premium on high‑margin growth. When the FDA approves an additional surgical platform, the stock often gaps up to 4% as investors re‑rate the company’s long‑term earnings potential. Monitoring the quarterly guidance on surgical device revenue and any regulatory milestones will signal whether the upside is sustained.
Drug Pipeline
The Innovative Medicine division’s oncology and immunology candidates remain the backbone of JNJ’s top‑line resilience, with several late‑stage trials now in the clinic. Q2 2026 revenue exceeded expectations by $0.1 billion, driven in part by a modest uptick in prescription sales from newly approved indications. Historically, the company’s drug pipeline has delivered 2–3% annual revenue growth, keeping EPS volatility at a manageable level. Each new approval tends to lift the stock by 2–3% as the market anticipates future cash flows, especially when the drug targets a high‑margin therapeutic area. Investors should watch for FDA advisory committee decisions and phase‑III trial results to gauge the pipeline’s impact on earnings.
Dividend Sustainability
Johnson & Johnson has maintained a 2.9% yield, with a 10‑year compound growth of 4.5% that keeps the yield‑on‑cost in the 6–7% range, as highlighted in recent dividend‑growth analysis. The company’s payout ratio hovers around 70%, giving it room to increase dividends even amid modest earnings swings. Historically, dividend hikes have driven a 1.5% to 2% bump in the share price on ex‑dividend dates, reflecting investor appetite for stable income. The falling sentiment trend suggests that some market participants are re‑evaluating the risk‑adjusted return, yet the dividend remains a key anchor for long‑term holders. Watch quarterly dividend announcements and any changes to the payout policy as early indicators of shareholder value direction.
Litigation Impact
The $5.5 billion talc settlement has already reduced cash reserves, and the company has committed to a $1 billion investment in contact‑lens manufacturing to offset the loss. Historically, large settlements have compressed earnings by 5–7% in the year following the payout, and the stock has trended down 3–4% in similar scenarios. The settlement also increased regulatory scrutiny, potentially affecting future product approvals and reimbursement negotiations. On earnings releases, the market reacts sharply to any guidance that acknowledges the settlement’s long‑term cash‑flow impact, often resulting in a 2–3% price correction. Investors should monitor the company’s cash‑flow statements and any updates on litigation risk to assess the durability of earnings.
Key insight: MedTech growth, particularly the OTTAVA system, remains the primary catalyst for Johnson & Johnson’s valuation, with the drug pipeline and dividend policy providing supporting layers. The recent talc settlement introduces a tangible drag, but the company’s cash reserves and strategic investments mitigate long‑term risk. Investors who focus on FDA milestones, revenue guidance, and dividend sustainability are likely to capture the most significant upside while remaining cognizant of the litigation backdrop.
Frequently Asked Questions About JNJ
What is the consensus target price for JNJ?
Analysts collectively target a price of $272.5 for JNJ, with a high of $305.0 and a low of $190.0, representing a potential upside of 28% from the current $259.72. The consensus is based on projected earnings growth and a valuation multiple that is 10% lower than the peer average. Out of 31 analysts, 22 recommend a buy, 9 hold, and none sell, reflecting strong confidence in the company’s fundamentals. The target range accounts for possible earnings volatility and regulatory risks. Investors should consider this consensus in the context of their risk tolerance and investment horizon.
Learn More
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
